UNSPSC 51172301: Deferoxamine

This classification denotes a metal chelator with the molecular formula C25H48N6O8, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J06Y7MXW4D, chemically known as 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy- but more generally known as deferoxamine, which bears U.S. National Institutes of Health Compound Identifier 2973. European Medicines Agency schedules Deferoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06942MIG.

World Health Organization schedules deferoxamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEFEROXAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51172301 Deferoxamine is a Commodity code that in practice covers drug testing services procured by state and local criminal justice and community supervision agencies. State and local governments buy laboratory specimen collection, immunoassay screening, confirmatory testing (LC/MS/MS and GC/MS), and alternative testing methodologies including oral fluid and hair testing under this code. Issuing bodies are primarily county departments of community supervision and corrections, drawing on criminal justice appropriations and community supervision funding streams. Vendors must maintain laboratory certification from SAMHSA, state drug-testing authorities, or CAP, and contracts typically run two to five years with annual price redetermination tied to medical Consumer Price Index increases capped at 3.0 percent.

Collin County, Texas, is the primary recent buyer on record. The county issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on September 25, 2026, with proposals due July 23, 2026, seeking screening and confirmatory testing across approximately 25,031 annual tests across five-panel and six-panel formats at two collection sites in Plano and McKinney. The estimated contract value is $600,000 over two years with three optional one-year renewals. Pricing is submitted on a per-test basis across three service models (screening only, confirmation after screening, and screening with automatic confirmation), with all freight, delivery, insurance, and staffing costs included and no surcharges permitted. Evaluation weighs vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional Phase 2 demonstrations and interviews (up to 30 points). The anticipated award date was August 10, 2026.